Industry
Biotechnology
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Loading...
Open
5.52
Mkt cap
260M
Volume
15K
High
5.52
P/E Ratio
13.08
52-wk high
6.42
Low
5.12
Div yield
N/A
52-wk low
3.08
Portfolio Pulse from Benzinga Newsdesk
September 19, 2024 | 8:15 pm
Portfolio Pulse from Benzinga Newsdesk
September 19, 2024 | 8:14 pm
Portfolio Pulse from Benzinga Newsdesk
July 29, 2024 | 10:13 am
Portfolio Pulse from Shivani Kumaresan
June 11, 2024 | 1:18 pm
Portfolio Pulse from Benzinga Newsdesk
June 11, 2024 | 12:43 pm
Portfolio Pulse from Benzinga Newsdesk
June 10, 2024 | 9:50 pm
Portfolio Pulse from Benzinga Newsdesk
June 10, 2024 | 9:26 pm
Portfolio Pulse from Benzinga Newsdesk
June 10, 2024 | 8:59 pm
Portfolio Pulse from Benzinga Newsdesk
June 10, 2024 | 8:42 pm
Portfolio Pulse from Benzinga Newsdesk
June 06, 2024 | 10:34 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.